The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Codelivery of Doxorubicin and Paclitaxel by Cross-Linked Multilamellar Liposome Enables Synergistic Antitumor Activity
Open accessAbstract
Combining chemotherapeutics is a promising method of improving cancer treatment; however, the clinical success of combination therapy is limited by the distinct pharmacokinetics of combined drugs, which leads to nonuniform distribution. In this study, we report a new robust approach to load two drugs with different hydrophilicities into a single cross-linked multilamellar liposomal vesicle (cMLV) to precisely control the drug ratio that reaches the tumor in vivo. The stability of cMLVs improves the loading efficiency and sustained release of doxorubicin (Dox) and paclitaxel (PTX), maximizing the combined therapeutic effect and minimizing the systemic toxicity. Furthermore, we show that the cMLV formulation maintains specific drug ratios in vivo for over 24 h, enabling the ratio-dependent combination synergy seen in vitro to translate to in vivo antitumor activity and giving us control over another parameter important to combination therapy. This combinatorial delivery system may provide a new strategy for synergistic delivery of multiple chemotherapeutics with a ratiometric control over encapsulated drugs to treat cancer and other diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Principles for the Buffering of Genetic Variation
Hartman IV, J. L. (2001) · Science · doi:10.1126/science.291.5506.1001 · Cited by 808
Multicomponent therapeutics for networked systems
Keith, C. T., Borisy, A. A., & Stockwell, B. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1609 · Cited by 769
Cited by
Ruan, S., Yuan, M., Zhang, L., Hu, G., Chen, J., Cun, X., Zhang, Q., Yang, Y., He, Q., & Gao, H. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.007 · Cited by 332
Liposome-based drug co-delivery systems in cancer cells
Zununi Vahed, S., Salehi, R., Davaran, S., & Sharifi, S. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2016.11.073 · Cited by 307
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101205 · Cited by 294
Camacho, K. M., Kumar, S., Menegatti, S., Vogus, D. R., Anselmo, A. C., & Mitragotri, S. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.031 · Cited by 97
Metadata
- Authors
- Liu, Y., Fang, J., Kim, Y.-J., Wong, M. K., & Wang, P.
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2014-04-07
- Volume
- 11
- Issue
- 5
- Pages
- 1651-1661
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2051024356
- Cited by
- 172
- References
- 5
- FWCI
- 8.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Codelivery of Doxorubicin and Paclitaxel by Cross-Linked Multilamellar Liposome Enables Synergistic Antitumor Activity. https://app.cochat.ai/papers/10.1021/mp5000373
- The paper
- Liu, Y., Fang, J., Kim, Y.-J., Wong, M. K., & Wang, P. (2014). Codelivery of Doxorubicin and Paclitaxel by Cross-Linked Multilamellar Liposome Enables Synergistic Antitumor Activity. Molecular Pharmaceutics. https://doi.org/10.1021/mp5000373
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.